IL94939A - Transformed Analogs of Maginin Peptide and Their Use - Google Patents

Transformed Analogs of Maginin Peptide and Their Use

Info

Publication number: IL94939A
Authority: IL; Israel
Prior art keywords: lys; ala; magainin; peptide; amino acid
Prior art date: 1989-07-07

Application number

IL9493990A

Other languages

English (en)

Hebrew (he)

Other versions

IL94939A0 (en

Original Assignee

Scripps Clinic Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-07

Filing date

1990-07-02

Publication date

1996-12-05

1990-07-02 Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res

1991-06-10 Publication of IL94939A0 publication Critical patent/IL94939A0/xx

1996-12-05 Publication of IL94939A publication Critical patent/IL94939A/en

Links

238000006467 substitution reaction Methods 0.000 title claims abstract description 53
108060003100 Magainin Proteins 0.000 title description 10
125000000539 amino acid group Chemical group 0.000 claims abstract description 139
OFIZOVDANLLTQD-ZVNXOKPXSA-N magainin i Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 OFIZOVDANLLTQD-ZVNXOKPXSA-N 0.000 claims abstract description 86
108091005128 magainin I Proteins 0.000 claims abstract description 67
101500009721 Xenopus laevis Magainin-2 Proteins 0.000 claims abstract description 60
150000001875 compounds Chemical class 0.000 claims abstract description 53
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 11
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 152
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 146
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 126
108090000765 processed proteins & peptides Proteins 0.000 claims description 82
MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 claims description 35
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 31
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 28
235000001014 amino acid Nutrition 0.000 claims description 27
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 25
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 21
150000001413 amino acids Chemical class 0.000 claims description 21
-1 Ala Chemical compound 0.000 claims description 20
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 17
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 15
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 15
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 14
239000004472 Lysine Substances 0.000 claims description 13
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 12
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims description 10
150000008574 D-amino acids Chemical group 0.000 claims description 10
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 7
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 7
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 7
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 7
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 7
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims description 4
230000000840 anti-viral effect Effects 0.000 claims description 4
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
108010030159 thrombin receptor peptide 14 Proteins 0.000 claims description 4
230000000845 anti-microbial effect Effects 0.000 claims description 3
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
230000001150 spermicidal effect Effects 0.000 claims description 3
229930195711 D-Serine Natural products 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
101100281510 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-6 gene Proteins 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 8
IMTUWVJPCQPJEE-IUCAKERBSA-N Met-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN IMTUWVJPCQPJEE-IUCAKERBSA-N 0.000 claims 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
230000000259 anti-tumor effect Effects 0.000 claims 2
ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 claims 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 claims 1
CZVQSYNVUHAILZ-UWVGGRQHSA-N His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 CZVQSYNVUHAILZ-UWVGGRQHSA-N 0.000 claims 1
FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 1
125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims 1
101100401106 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-7 gene Proteins 0.000 claims 1
JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 1
108010040030 histidinoalanine Proteins 0.000 claims 1
108010073969 valyllysine Proteins 0.000 claims 1
230000009036 growth inhibition Effects 0.000 description 79
241000588724 Escherichia coli Species 0.000 description 44
241000191963 Staphylococcus epidermidis Species 0.000 description 35
102000004196 processed proteins & peptides Human genes 0.000 description 22
229940024606 amino acid Drugs 0.000 description 19
235000004279 alanine Nutrition 0.000 description 11
150000001408 amides Chemical class 0.000 description 11
238000000034 method Methods 0.000 description 11
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
239000011347 resin Substances 0.000 description 9
229920005989 resin Polymers 0.000 description 9
235000013922 glutamic acid Nutrition 0.000 description 8
239000004220 glutamic acid Substances 0.000 description 8
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
238000010647 peptide synthesis reaction Methods 0.000 description 7
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
244000005700 microbiome Species 0.000 description 4
SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000000203 mixture Substances 0.000 description 3
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
150000008575 L-amino acids Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
238000002802 antimicrobial activity assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000005094 computer simulation Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229920004688 Altek® Polymers 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
VHWBWHBJEXGPNM-UHFFFAOYSA-N N(2)-(2,4-dichlorophenyl)-N-(7-{[(2,4-dichlorophenyl)amino]sulfonyl}-1-oxo-1,2-dihydronaphthalen-2-yl)glycinamide Chemical compound ClC1=CC(Cl)=CC=C1NCC(=O)NC1C(=O)C2=CC(S(=O)(=O)NC=3C(=CC(Cl)=CC=3)Cl)=CC=C2C=C1 VHWBWHBJEXGPNM-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
229940021746 d- serine Drugs 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000934 spermatocidal agent Substances 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL9493990A 1989-07-07 1990-07-02 Transformed Analogs of Maginin Peptide and Their Use IL94939A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37675489A	1989-07-07	1989-07-07

Publications (2)

Publication Number	Publication Date
IL94939A0 IL94939A0 (en)	1991-06-10
IL94939A true IL94939A (en)	1996-12-05

Family

ID=23486335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9493990A IL94939A (en)	1989-07-07	1990-07-02	Transformed Analogs of Maginin Peptide and Their Use

Country Status (16)

Country	Link
EP (4)	EP0437556B1 (fr)
JP (1)	JP2854970B2 (fr)
CN (1)	CN1055480C (fr)
AT (1)	ATE146188T1 (fr)
AU (1)	AU650236B2 (fr)
CA (1)	CA2020663C (fr)
DE (1)	DE69029377T2 (fr)
DK (1)	DK0437556T3 (fr)
ES (1)	ES2095255T3 (fr)
IE (1)	IE63842B1 (fr)
IL (1)	IL94939A (fr)
PH (4)	PH30054A (fr)
PT (1)	PT94625B (fr)
SG (1)	SG47913A1 (fr)
WO (1)	WO1991000869A1 (fr)
ZA (1)	ZA905203B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991000869A1 (fr) *	1989-07-07	1991-01-24	Scripps Clinic And Research Foundation	Analogues de substitution des peptides de la magainine
US5221664A (en) *	1990-04-23	1993-06-22	Magainin Pharmaaceuticals Inc.	Composition and treatment with biologically active peptides and toxic cations
AU648140B2 (en) *	1991-02-01	1994-04-14	Virtual Drug Development, Inc.	Reverse antimicrobial peptides and antimicrobial compositions
WO1992022317A1 (fr) *	1991-06-12	1992-12-23	Magainin Pharmaceuticals, Inc.	Composition de peptides biologiquement actifs presentant des substitutions au niveau de leur terminaison c et traitement a l'aide de ces peptides
US5424290A (en) *	1992-10-26	1995-06-13	Magainin Pharmaceuticals Inc.	Biologically active peptides and uses therefor
US5561107A (en) *	1993-06-04	1996-10-01	Demeter Biotechnologies, Ltd.	Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5773413A (en) *	1993-06-04	1998-06-30	Demeter Biotechnologies, Ltd.	Method of combating mammalian neoplasias, and lytic peptides therefor
CN101928340A (zh) *	2009-12-24	2010-12-29	深圳市圣西马生物技术有限公司	一组抗菌肽衍生物及其应用
CN104710523B (zh) *	2013-12-11	2017-12-29	华东理工大学	对铜绿假单胞菌具有抗菌性能的Magainin肽修饰物及其制备方法
KR20180022971A (ko) *	2015-07-02	2018-03-06	다나-파버 캔서 인스티튜트 인크.	안정화된 항미생물성 펩티드
WO2017151617A1 (fr)	2016-02-29	2017-09-08	Dana-Farber Cancer Institute, Inc.	Peptides antimicrobiens agrafés à ciblage intracellulaire pour traiter une infection
CA3067047A1 (fr) *	2017-07-19	2019-01-24	Dana-Farber Cancer Institute, Inc.	Peptides antimicrobiens stabilises pour le traitement d'infections bacteriennes resistantes aux antibiotiques
CN111892646B (zh) *	2020-08-13	2023-05-02	中国人民解放军军事科学院军事医学研究院	抗菌肽衍生物及其在制备抗细菌感染药物中的应用
CN112625092B (zh) *	2021-01-13	2023-03-28	兰州大学	一种基于polybia-MPI的抗菌多肽化合物及其合成与应用
CN114634553B (zh) *	2022-04-27	2024-03-08	贵州医科大学	阳离子肽c9及其应用
CN120081951B (zh) *	2025-03-06	2025-09-30	辽宁波尔莱特农牧实业集团有限公司	一种抗菌肽Magainin 2-hEGF融合蛋白及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU609118B2 (en) *	1987-03-04	1991-04-26	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	New synthetic bioactive compounds and method of producing bioactive effect
US4810777A (en)	1987-03-04	1989-03-07	The United States Of America As Represented By The Department Of Health And Human Services	Antimicrobial compounds
WO1991000869A1 (fr) *	1989-07-07	1991-01-24	Scripps Clinic And Research Foundation	Analogues de substitution des peptides de la magainine

1990
- 1990-06-28 WO PCT/US1990/003675 patent/WO1991000869A1/fr not_active Ceased
- 1990-06-28 EP EP90909538A patent/EP0437556B1/fr not_active Expired - Lifetime
- 1990-06-28 DE DE69029377T patent/DE69029377T2/de not_active Expired - Fee Related
- 1990-06-28 AT AT90909538T patent/ATE146188T1/de not_active IP Right Cessation
- 1990-06-28 EP EP96201385A patent/EP0751149A3/fr not_active Ceased
- 1990-06-28 DK DK90909538.2T patent/DK0437556T3/da active
- 1990-06-28 AU AU59454/90A patent/AU650236B2/en not_active Ceased
- 1990-06-28 EP EP96201383A patent/EP0761684A3/fr not_active Ceased
- 1990-06-28 SG SG1996005217A patent/SG47913A1/en unknown
- 1990-06-28 ES ES90909538T patent/ES2095255T3/es not_active Expired - Lifetime
- 1990-06-28 JP JP2509660A patent/JP2854970B2/ja not_active Expired - Fee Related
- 1990-06-28 EP EP96201384A patent/EP0751148A3/fr not_active Ceased
- 1990-07-02 IL IL9493990A patent/IL94939A/en active IP Right Grant
- 1990-07-03 ZA ZA905203A patent/ZA905203B/xx unknown
- 1990-07-06 IE IE247690A patent/IE63842B1/en not_active IP Right Cessation
- 1990-07-06 PH PH40802A patent/PH30054A/en unknown
- 1990-07-06 PT PT94625A patent/PT94625B/pt not_active IP Right Cessation
- 1990-07-06 CN CN90106803A patent/CN1055480C/zh not_active Expired - Fee Related
- 1990-07-06 CA CA002020663A patent/CA2020663C/fr not_active Expired - Lifetime
1992
- 1992-12-21 PH PH45488A patent/PH30218A/en unknown
- 1992-12-21 PH PH45486A patent/PH30219A/en unknown
- 1992-12-21 PH PH45487A patent/PH30410A/en unknown

Also Published As

Publication number	Publication date
ZA905203B (en)	1991-05-29
EP0751149A3 (fr)	1997-07-02
EP0437556B1 (fr)	1996-12-11
JP2854970B2 (ja)	1999-02-10
EP0437556A1 (fr)	1991-07-24
JPH04506801A (ja)	1992-11-26
AU650236B2 (en)	1994-06-16
ATE146188T1 (de)	1996-12-15
PH30054A (en)	1996-11-08
EP0751149A2 (fr)	1997-01-02
IE63842B1 (en)	1995-06-14
ES2095255T3 (es)	1997-02-16
PH30219A (en)	1997-02-05
DE69029377T2 (de)	1997-06-19
SG47913A1 (en)	1998-04-17
PT94625A (pt)	1991-03-20
DK0437556T3 (da)	1996-12-30
DE69029377D1 (de)	1997-01-23
CN1049166A (zh)	1991-02-13
IE902476A1 (en)	1991-02-13
CN1055480C (zh)	2000-08-16
AU5945490A (en)	1991-02-06
WO1991000869A1 (fr)	1991-01-24
EP0751148A3 (fr)	1997-07-02
CA2020663C (fr)	1999-12-07
EP0751148A2 (fr)	1997-01-02
PT94625B (pt)	1997-03-31
PH30218A (en)	1997-02-05
EP0761684A2 (fr)	1997-03-12
PH30410A (en)	1997-05-09
CA2020663A1 (fr)	1991-01-08
EP0437556A4 (en)	1992-05-20
IL94939A0 (en)	1991-06-10
EP0761684A3 (fr)	1997-07-02

Legal Events

Date	Code	Title
1997-06-10	FF	Patent granted
1998-01-04	KB	Patent renewed
2000-11-21	KB	Patent renewed
2004-09-27	KB	Patent renewed
2008-11-27	KB	Patent renewed

Publication	Publication Date	Title
US5294605A (en)	1994-03-15	Amphiphilic peptide compositions and analogues thereof
US4962277A (en)	1990-10-09	Deletion analogues of magainin peptides
JP3266311B2 (ja)	2002-03-18	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
EP0437556B1 (fr)	1996-12-11	Analogues de substitution des peptides de la magainine
KR0184604B1 (ko)	1999-05-01	신규한 폴리펩타이드 및 그것으로 제조한 항-hiv약제
EP1386928B1 (fr)	2015-10-14	Derive peptidique antibacterien de peau de grenouille
US5912231A (en)	1999-06-15	Substitution analogues of magainin peptides
EP2548883A2 (fr)	2013-01-23	Composés peptidiques utiles en tant qu'agents antibactériens
WO1998016549A1 (fr)	1998-04-23	Analogues de peptides anti-microbiens de gramicidine s et compositions contenant ces analogues
WO1989011290A1 (fr)	1989-11-30	Peptides amphiphiliques et leur utilisation
CN119350445B (zh)	2025-11-04	一种基于Tritrpticin的衍生抗菌肽及其合成方法和在抗菌方面的应用
CA2047317A1 (fr)	1992-01-20	Compositions peptidiques amphiphiliques et leurs analogues
US7723467B2 (en)	2010-05-25	Antimicrobial compounds
WO1991019512A1 (fr)	1991-12-26	Peptides antimicrobiens
JPH0656889A (ja)	1994-03-01	新規ペプチドおよび抗菌剤
US4330465A (en)	1982-05-18	Novel β-endorphin analogs
CN120058864A (zh)	2025-05-30	Peg化抗菌肽制备及其在细菌感染中的应用
CN115010788A (zh)	2022-09-06	N-末端脂肪酸修饰的具有抗生物膜活性的低毒广谱抗菌肽类似物及其应用
JPH06199893A (ja)	1994-07-19	新規ペプチドおよび抗菌剤
JPH0656888A (ja)	1994-03-01	新規ペプチドおよび抗菌剤
JP2005532784A (ja)	2005-11-04	新規の抗菌ボリシンペプチド
NO904846L (no)	1990-11-07	Amfifile peptider og anvendelse derav.